METHOD AND PROBE SET FOR DETECTING CANCER
Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
1 . A method of screening for cancer in a subject comprising:
(a) hybridizing a set of chromosomal probes to a biological sample from said subject;
(b) selecting cells from said biological sample;
(c) determining the presence or absence of aneusomic cells in said selected cells;
(d) correlating presence of aneusomic cells in the selected cells with cancer in said subject.
2 . The method of claim 1 , wherein said biological sample is selected from the group consisting of urine, blood, cerebrospinal fluid, pleural fluid, sputum, peritoneal fluid, bladder washings, oral washings, tissue samples, touch preps, and fine-needle aspirates.
3 . The method of claim 1 , wherein said biological sample is concentrated.
4 . The method of claim 1 , wherein said biological sample is urine.
5 . The method of claim 1 , wherein said cancer is selected from the group consisting of bladder cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, renal cancer, and leukemia.
6 . The method of claim 1 , wherein said cancer is bladder cancer.
7 . The method of claim 1 , wherein said chromosomal probes are fluorescently labeled.
8 . The method of claim 1 , wherein said set comprises at least three chromosomal probes.
9 . The method of claim 1 , wherein said set comprises at least one centromeric probe.
10 . The method of claim 9 , wherein said set further comprises at least one locus specific probe.
11 . The method of claim 9 , wherein said centromeric chromosomal probes are selected from the group consisting of chromosomal probes 3, 7, 8, 11, 15, 17, 18, and Y.
12 . The method of claim 10 , wherein said locus specific probe is 9p21.
13 . The method of claim 8 , wherein said set comprises chromosomal probes 3, 7, and 17.
14 . The method of claim 13 , wherein said set further comprises locus specific probe 9p21.
15 . The method of claim 1 , wherein cells are selected by nuclear morphology.
16 . The method of claim 1 , wherein cells are selected by nuclear size.
17 . The method of claim 1 , wherein cells are selected by shape of nucleus.
18 . The method of claim 15 , wherein nuclear morphology is assessed by DAPI staining.
19 . A set of chromosomal probes, said set comprising centromeric probes to chromosomes 3, 7, and 17.
20 . The set of chromosomal probes of claim 19 , said set further comprising a locus-specific probe.
21 . The set of chromosomal probes of claim 20 , wherein said locus-specific probe is 9p21.
22 . A kit for detecting cancer, said kit comprising a set of chromosomal probes, wherein said set comprises centromeric probes to chromosomes 3, 7, and 17.
23 . The kit of claim 22 , said kit further comprising a locus-specific probe.
24 . The kit of claim 23 , wherein said locus-specific probe is 9p21.
25 . The kit of claim 22 , wherein said chromosomal probes are fluorescently labeled.